Fig. 7

CCR2⁺HSC-derived dendritic cells expand T-cells in adoptive cell therapy. a Experimental description. b Cells derived from GFP⁺HSCs, GFP⁺CCR2⁻HSCs, or GFP⁺CCR2⁺HSCs were isolated from the tumors of mice treated with adoptive cell therapy. These were then used as a vaccine in a second cohort of mice treated with adoptive cell therapy using DsRed + tumor-reactive T cells. Vaccine draining lymph nodes were harvested and relative amounts of DsRed⁺ T-cells were measured between the group that received CCR2⁺HSCs and the groups that received cells derived from CCR2⁻HSCs (*p = 0.0001, t-test, n = 3 replicates per group). All error bars represent s.e.m.